Literature DB >> 2787130

Hemodynamic and cardiodynamic effects of propofol and etomidate: negative inotropic properties of propofol.

T Brüssel1, J L Theissen, G Vigfusson, P P Lunkenheimer, H Van Aken, P Lawin.   

Abstract

The hemodynamic effects of an induction dose of propofol, 2.5 mg/kg, or etomidate, 0.3 mg/kg, were studied in eight dogs. In addition, cardiodynamic changes were measured using a left ventricular catheter and needle force probes. Propofol was associated with significant decreases in systolic (19.9%) and diastolic (25.3%) arterial pressures associated with a 17.3% decrease in cardiac output (CO) and a 11.6% reduction in systemic vascular resistance (SVR) without change in pulmonary capillary wedge pressure (PCWP). These changes were most pronounced 1 min after the injection of propofol. At 5 and 10 min after the administration of propofol, heart rate (HR) decreased significantly. Minimal changes in hemodynamics were observed with etomidate. Propofol lowered systolic left ventricular pressure (LVPsys) by 17.6%. Signals generated by the force probes in the left ventricular myocardium showed a significant reduction (16.3%) in left ventricular force (LVF) and a decrease in early systolic rates of increase in force (dF/dt max) by 23.5% associated with propofol. In the presence of an unchanged preload, an unchanged HR, and a decreased SVR, the reduction in CO suggests that propofol has a negative inotropic effect. This negative inotropic effect was confirmed by a reduction in LVF and dF/dt max.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787130

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  25 in total

1.  The differential effect of propofol on contractility of isolated myocardial trabeculae of rat and guinea-pig.

Authors:  J van Klarenbosch; G J Stienen; W de Ruijter; G J Scheffer; J J de Lange
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

2.  The effect of opioid and acepromazine premedication on the anesthetic induction dose of propofol in cats.

Authors:  T L Hall; T Duke; H G Townsend; N A Caulkett; S L Cantwell
Journal:  Can Vet J       Date:  1999-12       Impact factor: 1.008

Review 3.  Sedation and analgesia in paediatric intensive care units: a guide to drug selection and use.

Authors:  J D Tobias
Journal:  Paediatr Drugs       Date:  1999 Apr-Jun       Impact factor: 3.022

4.  Arterial baroreflex attenuation during and after continuous propofol infusion.

Authors:  Y Kamijo; H Goto; K Nakazawa; K T Benson; K Arakawa
Journal:  Can J Anaesth       Date:  1992-11       Impact factor: 5.063

5.  Efficacy and safety of periprostatic nerve block combined with perineal subcutaneous anaesthesia and intrarectal lidocaine gel in transrectal ultrasound guided transperineal prostate biopsy: A Prospective Randomised Controlled Trial.

Authors:  Zhengtong Lv; Huichuan Jiang; Xiheng Hu; Changzhao Yang; Harripersaud Chand; Congyi Tang; Yuan Li
Journal:  Prostate Cancer Prostatic Dis       Date:  2019-06-03       Impact factor: 5.554

6.  Propofol infusion-like syndrome in a dog.

Authors:  John M Mallard; Teresa M Rieser; Nathan W Peterson
Journal:  Can Vet J       Date:  2018-11       Impact factor: 1.008

Review 7.  Update on the 2012 guidelines for the management of pediatric traumatic brain injury - information for the anesthesiologist.

Authors:  Nina Hardcastle; Hubert A Benzon; Monica S Vavilala
Journal:  Paediatr Anaesth       Date:  2014-05-12       Impact factor: 2.556

Review 8.  Propofol in patients with cardiac disease.

Authors:  N R Searle; P Sahab
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

Review 9.  [Propofol infusion syndrome].

Authors:  J Motsch; J Roggenbach
Journal:  Anaesthesist       Date:  2004-10       Impact factor: 1.041

10.  Propofol regulation of calcium entry pathways in cultured A10 and rat aortic smooth muscle cells.

Authors:  Y T Xuan; P S Glass
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.